Developer docs
API playgroundTry for free, no card

Search company profiles

Concord Biotech

Full company profile

uuid0008usr

Namestring
Concord Biotech
Legal namestring
Concord Biotech Limited
Company typeenum
Public
Founded yearint
2000
Descriptiontext

Concord Biotech Limited is a vertically integrated biopharmaceutical company headquartered in Ahmedabad, Gujarat, India, specializing in the development, manufacturing, and commercialization of fermentation-based Active Pharmaceutical Ingredients (APIs) and finished dosage formulations. Founded in 2000 by Sudhir Vaid, the company operates four manufacturing facilities across Gujarat — Units I (Dholka, API), II (Valthera, oral solid dosage formulations), III (Limbasi, API, described as one of the largest fermentation-based API plants in Asia), and IV (Valthera, injectable facility commissioned 2025) — supported by DSIR-certified R&D facilities in microbiology, fermentation, and formulation development. Its portfolio covers 30+ fermentation-based APIs across immunosuppressants (Tacrolimus, Mycophenolate Mofetil, Cyclosporine, Sirolimus), oncology (Temsirolimus, Everolimus, Doxorubicin), anti-bacterials (Mupirocin, Teicoplanin, Vancomycin, Daptomycin), and anti-fungals (Anidulafungin, Micafungin, Caspofungin, Amphotericin B), with combined fermentation capacity of 1,250 m³ and 802 million units/year of oral solid dosage capacity.

The company generates revenue through three streams: (i) API manufacturing and B2B sales to global pharmaceutical companies, (ii) finished formulations marketed globally (regulated markets via USFDA-approved ANDAs through subsidiary Stellon Biotech Inc. and generic formulations in emerging markets) and in India under branded generics under the INCA (critical care) and Conquest (nephrology, hematology, rheumatology) sub-brands, and (iii) Contract Research and Manufacturing Services (CRAM) offering strain improvement, media optimization, process development, and scale-up for fermentation and semi-synthetic products. Pricing is quote-based B2B with no public disclosure. Concord serves 250+ global customers across 70+ countries and holds regulatory approvals from USFDA, EU GMP, Japan PMDA, Brazil ANVISA, Korea MFDS, and others, enabling access to regulated and emerging markets.

Concord Biotech is publicly listed on BSE and NSE (ticker CONCORDBIO) since August 2023 and employs 501-1,000 people. The founder Sudhir Vaid serves as Chairman and Managing Director, with his son Ankur Vaid as Joint MD & CEO. The estate of late investor Rakesh Jhunjhunwala holds an estimated 24% stake (valued at approximately Rs 2,854 crore as of early 2026), making it the most significant external shareholder alongside Rare Enterprises (RARE Trusts). Recent strategic activity includes USFDA ANDA approvals in 2025-2026 for Teriflunomide, Mycophenolate Mofetil oral suspension, and Tofacitinib Tablets (targeting a combined ~$530M US market opportunity), the April 2026 acquisition of Celliimmune Biotech for entry into DNA engineering / cancer therapeutics, and renewable energy investments at the Limbasi and Dholka facilities.

Short descriptiontext

Concord Biotech Limited is an India-based, publicly listed biopharmaceutical company that develops and manufactures fermentation-based APIs (immunospressants, oncology, anti-infectives) and finished formulations for global pharmaceutical companies across 70+ countries, operating four manufacturing facilities in Gujarat.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersAhmedabad, India
HQ citystring
Ahmedabad
HQ countrystring
India
HQ regionstring
Asia
Markets served

Serves global market

Offices6 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
active pharmaceutical ingredients, fermentation-based biopharmaceuticals, generic drug formulations, contract manufacturing services, immunosuppressant manufacturing
Industry3 codes
PRIMARYHLAGABAA
Small-Molecule API & Intermediates CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAIABAG
Generic APIs & Intermediates (Active Ingredients)
SECONDARYHLAIABAH
Generic Finished Dosage Form (FDF) Manufacturing
NAICS code4 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing32541
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
Biopharmaceutical Manufacturing
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1API Manufacturing & Sales
TypeOne Time License
Description

Manufacturing and selling fermentation-based Active Pharmaceutical Ingredients to global pharmaceutical companies. Products include immunosuppressants (Tacrolimus, Mycophenolate Mofetil, Cyclosporine), oncology drugs (Temsirolimus, Everolimus), anti-bacterials (Mupirocin, Teicoplanin), and anti-fungals (Anidulafungin, Micafungin). Revenue generated through direct B2B sales to pharmaceutical manufacturers across regulated and emerging markets.

concordbiotech.com
2Finished Formulations
TypeOne Time License
Description

Manufacturing and selling finished dosage forms including oral solids (tablets, capsules - 802 million units/year capacity), oral liquids, and injectables. Products marketed in India under own brands and distributed globally through partnerships in regulated and emerging markets.

concordbiotech.com
3Contract Research & Manufacturing (CRAM)
TypeProfessional Services
Description

Providing contract research and manufacturing services to global pharmaceutical companies. Services include strain improvement, media optimization, process development, scale-up, and manufacturing for fermentation and semi-synthetic products. Also offers formulation development and contract manufacturing for diverse dosage forms.

concordbiotech.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Operations, Supply Chain, Personnel, Technology or R&D, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1INCA
Description

Intensive care brand covering Antifungal, Antibiotics, and other critical care product portfolios for the Indian market.

concordbiotech.com
+1 more record
Core offering1 text field

Concord Biotech Limited develops, manufactures, and commercializes fermentation-based Active Pharmaceutical Ingredients (APIs) and finished formulations across immunosuppressants, oncology, anti-bacterials, and anti-fungals. The company operates four manufacturing facilities in Gujarat, India with 1,250 m³ combined fermentation capacity and 802 million units/year oral solid dosage capacity, supplying global pharmaceutical companies through direct B2B sales and USFDA-approved ANDAs. It also provides Contract Research and Manufacturing Services (CRAM) to pharmaceutical partners globally.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Successfully completed ANVISA inspection at Limbasi API facility (June 8-12, 2026)
+3 more records
Product overview1 text field

Concord Biotech Limited is a biopharmaceutical company specializing in fermentation-based Active Pharmaceutical Ingredients (APIs) and finished formulations. The company operates four manufacturing facilities in Gujarat, India, with a combined fermentation capacity of 1,250 M3. Its product portfolio includes over 30 fermentation-based APIs across immunosuppressants (Tacrolimus, Mycophenolate Mofetil, Cyclosporine, Sirolimus), oncology (Temsirolimus, Everolimus, Doxorubicin), anti-bacterials (Mupirocin, Teicoplanin, Vancomycin, Daptomycin), and anti-fungals (Anidulafungin, Micafungin, Amphotericin B). The formulations business comprises Global Formulations (USFDA-approved ANDAs for regulated markets, generic formulations for emerging markets) and Branded Generic India products across Critical Care, Transplant/Immunology/Nephrology, and Rheumatology segments. The company also provides Contract Research & Manufacturing (CRAM) services through DSIR-certified R&D facilities. Products are sold in over 70 countries worldwide.

Product and service10 records
1Fermentation-based Active Pharmaceutical Ingredients (APIs)
CategoryActive Pharmaceutical Ingredients
Description

Niche fermentation and semi-synthetic APIs manufactured at the Dholka and Limbasi facilities with combined 1,250 m³ fermentation capacity. Sold to global pharmaceutical manufacturers across regulated markets (US, Europe, Japan) and emerging markets for use in finished drug formulations.

2Tacrolimus Capsules USP (0.5mg, 1mg, 5mg)
CategoryGlobal Formulations (USFDA ANDAs)
Description

Generic immunosuppressant capsule formulation for transplant patients, marketed in the US through Stellon Biotech Inc. subsidiary under USFDA ANDA approval.

3Mycophenolate Mofetil Capsules USP 250mg
CategoryGlobal Formulations (USFDA ANDAs)
Description

Generic immunosuppressant capsule used for prophylaxis of organ rejection in transplant recipients, marketed in the US through Stellon Biotech Inc.

4Mycophenolate Mofetil Tablets USP 500mg
CategoryGlobal Formulations (USFDA ANDAs)
Description

Generic immunosuppressant tablet for organ transplant patients, sold in the US market via Stellon Biotech Inc.

5Mycophenolic Acid DR Tablets USP (180mg, 360mg)
CategoryGlobal Formulations (USFDA ANDAs)
Description

Delayed-release generic immunosuppressant tablet formulation used for transplant patients, marketed in the US through Stellon Biotech Inc.

6Mycophenolate Mofetil for Oral Suspension USP 200 mg/mL
CategoryGlobal Formulations (USFDA ANDAs)
Description

Oral suspension formulation of immunosuppressant marketed through US subsidiary Stellon Biotech Inc.; targeted at transplant patient populations including pediatric patients.

7Tofacitinib Tablets (5mg, 10mg)
CategoryGlobal Formulations (USFDA ANDAs)
Description

Generic Janus kinase inhibitor tablet for autoimmune and inflammatory conditions, sold in the US market targeting a $500 million opportunity.

8Teriflunomide Tablets USP (7mg, 14mg)
CategoryGlobal Formulations (USFDA ANDAs)
Description

Generic immunomodulatory tablet for multiple sclerosis treatment, marketed in the US through Stellon Biotech Inc.

9Branded Generic India Products (INCA and INTRA portfolios)
CategoryIndia Branded Generics
Description

High-quality branded generic formulations tailored for the Indian healthcare market covering critical care, transplant, immunology, nephrology, and rheumatology segments. Marketed through domestic sales channels to Indian healthcare providers.

10Contract Research & Manufacturing (CRAM) Services
CategoryContract Development & Manufacturing Services
Description

Contract development and manufacturing services for global pharmaceutical companies covering API CRAM (fermentation, semi-synthesis, strain improvement, media optimization, process development, scale-up) and Formulation CRAM (pre-formulation, sterile/non-sterile dosage forms including oral solids, injectables, and lyophilized formulations) using DSIR-certified R&D facilities.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2021-08-13
Description

MoU signed for setting up Rs. 500 crore fermentation-based API manufacturing plant in Una District, Himachal Pradesh. Represents significant capacity expansion initiative.

2Celliimmune Biotech Private Limited
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Concord Biotech acquired 100% of Celliimmune Biotech Private Limited for ₹66,00,000 to advance research in DNA engineering for cancer therapeutics.

scanx.trade
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Strategic investment in US-based Palvella Therapeutics, Inc. for potential partnership and market expansion opportunities.

Strategic tierMinorTypeOthers
Description

CSR partnership where Concord Biotech donated 2 electric SUVs to AIIMS for green energy initiative and patient transport between campuses.

Strategic tierMinorTypeOthers
Description

CSR partnership for green initiative including development and maintenance of public park (Oxygen Garden) spanning approximately 75,000 sq.ft. with over 1,000 plants and shrubs.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

India-based biopharmaceutical company with a deep fermentation, biologics, and APIs business. Directly comparable to Concord's fermentation-based API and complex formulation focus, and an obvious Indian-headquartered peer for CRAM and immunosuppressant segments.

TypeDirect peer
Description

Large Indian generic manufacturer with substantial fermentation-derived API capacity and USFDA-approved sterile injectables. Overlaps with Concord on fermentation-based APIs (steroids, anti-infectives) and finished formulations across regulated markets.

TypeDirect peer
Description

India-headquartered global generics and API company with strong US presence and active pharmaceutical ingredient operations. Competes with Concord across immunosuppressants, anti-infectives, and other complex generic categories.

TypeDirect peer
Description

Indian specialty generics company with oncology, immunosuppressant, and complex API focus. Comparable to Concord in niche complex generics and in competing for USFDA ANDA approvals in regulated therapeutic segments.

5Sun Pharmaceutical Industries
TypeBroad incumbent
Description

India's largest pharmaceutical company with a broad generics, specialty, and API portfolio including sterile injectables and fermentation-derived products. Operates as a much larger incumbent that overlaps with Concord in immunosuppressants and global generics.

TypeBroad incumbent
Description

Large Indian generics and API manufacturer with USFDA-approved manufacturing. Overlaps with Concord in APIs and complex formulations across regulated and emerging markets; broader portfolio but similar regulated-market strategy.

TypeEmerging player
Description

CDMO arm of Piramal Pharma with strong contract development and manufacturing capabilities for APIs and sterile injectables. Direct competitor to Concord's CRAM business, particularly for fermentation and complex injectable CDMO engagements.

8Recipharm
TypeBroad incumbent
Description

Global CDMO with sterile fill-finish and API capabilities. Comparable to Concord on the CRAM/formulation side for global pharma companies seeking outsourced sterile manufacturing.

TypeRegional player
Description

India-based specialty generics company focused on softgel, oral solids, and other regulated-market formulations. Comparable to Concord's formulation business in regulatory complexity and emerging/regulated market reach.

TypeOthers
Description

Indian fermentation-based API and animal health manufacturer with significant fermentation capabilities. Adjacent peer sharing the fermentation platform technology paradigm relevant to Concord's API manufacturing.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries6 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance11 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Concord Biotech

Biopharmaceutical Manufacturingconcordbiotech.com

Concord Biotech Limited is an India-based, publicly listed biopharmaceutical company that develops and manufactures fermentation-based APIs (immunospressants, oncology, anti-infectives) and finished formulations for global pharmaceutical companies across 70+ countries, operating four manufacturing facilities in Gujarat.

What Concord Biotech does

Concord Biotech Limited is a vertically integrated biopharmaceutical company headquartered in Ahmedabad, Gujarat, India, specializing in the development, manufacturing, and commercialization of fermentation-based Active Pharmaceutical Ingredients (APIs) and finished dosage formulations. Founded in 2000 by Sudhir Vaid, the company operates four manufacturing facilities across Gujarat — Units I (Dholka, API), II (Valthera, oral solid dosage formulations), III (Limbasi, API, described as one of the largest fermentation-based API plants in Asia), and IV (Valthera, injectable facility commissioned 2025) — supported by DSIR-certified R&D facilities in microbiology, fermentation, and formulation development. Its portfolio covers 30+ fermentation-based APIs across immunosuppressants (Tacrolimus, Mycophenolate Mofetil, Cyclosporine, Sirolimus), oncology (Temsirolimus, Everolimus, Doxorubicin), anti-bacterials (Mupirocin, Teicoplanin, Vancomycin, Daptomycin), and anti-fungals (Anidulafungin, Micafungin, Caspofungin, Amphotericin B), with combined fermentation capacity of 1,250 m³ and 802 million units/year of oral solid dosage capacity.

The company generates revenue through three streams: (i) API manufacturing and B2B sales to global pharmaceutical companies, (ii) finished formulations marketed globally (regulated markets via USFDA-approved ANDAs through subsidiary Stellon Biotech Inc. and generic formulations in emerging markets) and in India under branded generics under the INCA (critical care) and Conquest (nephrology, hematology, rheumatology) sub-brands, and (iii) Contract Research and Manufacturing Services (CRAM) offering strain improvement, media optimization, process development, and scale-up for fermentation and semi-synthetic products. Pricing is quote-based B2B with no public disclosure. Concord serves 250+ global customers across 70+ countries and holds regulatory approvals from USFDA, EU GMP, Japan PMDA, Brazil ANVISA, Korea MFDS, and others, enabling access to regulated and emerging markets.

Concord Biotech is publicly listed on BSE and NSE (ticker CONCORDBIO) since August 2023 and employs 501-1,000 people. The founder Sudhir Vaid serves as Chairman and Managing Director, with his son Ankur Vaid as Joint MD & CEO. The estate of late investor Rakesh Jhunjhunwala holds an estimated 24% stake (valued at approximately Rs 2,854 crore as of early 2026), making it the most significant external shareholder alongside Rare Enterprises (RARE Trusts). Recent strategic activity includes USFDA ANDA approvals in 2025-2026 for Teriflunomide, Mycophenolate Mofetil oral suspension, and Tofacitinib Tablets (targeting a combined ~$530M US market opportunity), the April 2026 acquisition of Celliimmune Biotech for entry into DNA engineering / cancer therapeutics, and renewable energy investments at the Limbasi and Dholka facilities.

Concord Biotech firmographics

Firmographics
Name
Concord Biotech
Legal name
Concord Biotech Limited
Website
https://concordbiotech.com
Company type
Public
Founded year
2000
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
Concord Biotech Limited is an India-based, publicly listed biopharmaceutical company that develops and manufactures fermentation-based APIs (immunospressants, oncology, anti-infectives) and finished formulations for global pharmaceutical companies across 70+ countries, operating four manufacturing facilities in Gujarat.
Ownership category
akta.pro rank

Concord Biotech industry classification

Industry
Product category
Biopharmaceutical Manufacturing
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (32541)
SIC
Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGABAA
Small-Molecule API & Intermediates CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAIABAG
Generic APIs & Intermediates (Active Ingredients)
SECONDARYHLAIABAH
Generic Finished Dosage Form (FDF) Manufacturing

Keywords

  • Active pharmaceutical ingredients
  • Fermentation-based biopharmaceuticals
  • Generic drug formulations
  • Contract manufacturing services
  • Immunosuppressant manufacturing

Where Concord Biotech is headquartered

Location

Headquarters

HQ city
Ahmedabad
HQ country
India
HQ region
Asia

Offices6 records

Markets served

Concord Biotech business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Supply Chain, Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. API Manufacturing & Sales: Manufacturing and selling fermentation-based Active Pharmaceutical Ingredients to global pharmaceutical companies. Products include immunosuppressants (Tacrolimus, Mycophenolate Mofetil, Cyclosporine), oncology drugs (Temsirolimus, Everolimus), anti-bacterials (Mupirocin, Teicoplanin), and anti-fungals (Anidulafungin, Micafungin). Revenue generated through direct B2B sales to pharmaceutical manufacturers across regulated and emerging markets.
  2. Finished Formulations: Manufacturing and selling finished dosage forms including oral solids (tablets, capsules - 802 million units/year capacity), oral liquids, and injectables. Products marketed in India under own brands and distributed globally through partnerships in regulated and emerging markets.
  3. Contract Research & Manufacturing (CRAM): Providing contract research and manufacturing services to global pharmaceutical companies. Services include strain improvement, media optimization, process development, scale-up, and manufacturing for fermentation and semi-synthetic products. Also offers formulation development and contract manufacturing for diverse dosage forms.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Concord Biotech product offering

Product offering

Core offering

Concord Biotech Limited develops, manufactures, and commercializes fermentation-based Active Pharmaceutical Ingredients (APIs) and finished formulations across immunosuppressants, oncology, anti-bacterials, and anti-fungals. The company operates four manufacturing facilities in Gujarat, India with 1,250 m³ combined fermentation capacity and 802 million units/year oral solid dosage capacity, supplying global pharmaceutical companies through direct B2B sales and USFDA-approved ANDAs. It also provides Contract Research and Manufacturing Services (CRAM) to pharmaceutical partners globally.

Product overview

Concord Biotech Limited is a biopharmaceutical company specializing in fermentation-based Active Pharmaceutical Ingredients (APIs) and finished formulations. The company operates four manufacturing facilities in Gujarat, India, with a combined fermentation capacity of 1,250 M3. Its product portfolio includes over 30 fermentation-based APIs across immunosuppressants (Tacrolimus, Mycophenolate Mofetil, Cyclosporine, Sirolimus), oncology (Temsirolimus, Everolimus, Doxorubicin), anti-bacterials (Mupirocin, Teicoplanin, Vancomycin, Daptomycin), and anti-fungals (Anidulafungin, Micafungin, Amphotericin B). The formulations business comprises Global Formulations (USFDA-approved ANDAs for regulated markets, generic formulations for emerging markets) and Branded Generic India products across Critical Care, Transplant/Immunology/Nephrology, and Rheumatology segments. The company also provides Contract Research & Manufacturing (CRAM) services through DSIR-certified R&D facilities. Products are sold in over 70 countries worldwide.

Differentiator

Problem solved

Functional benefit

Brands

  • INCA: Intensive care brand covering Antifungal, Antibiotics, and other critical care product portfolios for the Indian market.
  • Conquest

Products and services

  • Fermentation-based Active Pharmaceutical Ingredients (APIs) Niche fermentation and semi-synthetic APIs manufactured at the Dholka and Limbasi facilities with combined 1,250 m³ fermentation capacity. Sold to global pharmaceutical manufacturers across regulated markets (US, Europe, Japan) and emerging markets for use in finished drug formulations.
  • Tacrolimus Capsules USP (0.5mg, 1mg, 5mg) Generic immunosuppressant capsule formulation for transplant patients, marketed in the US through Stellon Biotech Inc. subsidiary under USFDA ANDA approval.
  • Mycophenolate Mofetil Capsules USP 250mg Generic immunosuppressant capsule used for prophylaxis of organ rejection in transplant recipients, marketed in the US through Stellon Biotech Inc.
  • Mycophenolate Mofetil Tablets USP 500mg Generic immunosuppressant tablet for organ transplant patients, sold in the US market via Stellon Biotech Inc.
  • Mycophenolic Acid DR Tablets USP (180mg, 360mg) Delayed-release generic immunosuppressant tablet formulation used for transplant patients, marketed in the US through Stellon Biotech Inc.
  • Mycophenolate Mofetil for Oral Suspension USP 200 mg/mL Oral suspension formulation of immunosuppressant marketed through US subsidiary Stellon Biotech Inc.; targeted at transplant patient populations including pediatric patients.
  • Tofacitinib Tablets (5mg, 10mg) Generic Janus kinase inhibitor tablet for autoimmune and inflammatory conditions, sold in the US market targeting a $500 million opportunity.
  • Teriflunomide Tablets USP (7mg, 14mg) Generic immunomodulatory tablet for multiple sclerosis treatment, marketed in the US through Stellon Biotech Inc.
  • Branded Generic India Products (INCA and INTRA portfolios) High-quality branded generic formulations tailored for the Indian healthcare market covering critical care, transplant, immunology, nephrology, and rheumatology segments. Marketed through domestic sales channels to Indian healthcare providers.
  • Contract Research & Manufacturing (CRAM) Services Contract development and manufacturing services for global pharmaceutical companies covering API CRAM (fermentation, semi-synthesis, strain improvement, media optimization, process development, scale-up) and Formulation CRAM (pre-formulation, sterile/non-sterile dosage forms including oral solids, injectables, and lyophilized formulations) using DSIR-certified R&D facilities.

Quantifiable outcome

  • Successfully completed ANVISA inspection at Limbasi API facility (June 8-12, 2026)
  • +3 more outcomes

Companies that use Concord Biotech

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Concord Biotech technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Concord Biotech partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered major and minor.

  • Himachal Pradesh State GovernmentmajorStrategic or Co-development Partner · 13 August 2021MoU signed for setting up Rs. 500 crore fermentation-based API manufacturing plant in Una District, Himachal Pradesh. Represents significant capacity expansion initiative.
  • Celliimmune Biotech Private LimitedminorStrategic or Co-development PartnerConcord Biotech acquired 100% of Celliimmune Biotech Private Limited for ₹66,00,000 to advance research in DNA engineering for cancer therapeutics.
  • Palvella Therapeutics, Inc.minorStrategic or Co-development PartnerStrategic investment in US-based Palvella Therapeutics, Inc. for potential partnership and market expansion opportunities.
  • AIIMS New DelhiminorOthersCSR partnership where Concord Biotech donated 2 electric SUVs to AIIMS for green energy initiative and patient transport between campuses.
  • IKDRC-ITS (Institute of Kidney Disease & Research Centre)minorOthersCSR partnership for green initiative including development and maintenance of public park (Oxygen Garden) spanning approximately 75,000 sq.ft. with over 1,000 plants and shrubs.

Scale indicators11 records

Recent moves7 records

Expansion highlights5 records

Concord Biotech competitors and assessment

Company assessment

Direct peers

  • Biocon Limited: India-based biopharmaceutical company with a deep fermentation, biologics, and APIs business. Directly comparable to Concord's fermentation-based API and complex formulation focus, and an obvious Indian-headquartered peer for CRAM and immunosuppressant segments.
  • Aurobindo Pharma: Large Indian generic manufacturer with substantial fermentation-derived API capacity and USFDA-approved sterile injectables. Overlaps with Concord on fermentation-based APIs (steroids, anti-infectives) and finished formulations across regulated markets.
  • Dr. Reddy's Laboratories: India-headquartered global generics and API company with strong US presence and active pharmaceutical ingredient operations. Competes with Concord across immunosuppressants, anti-infectives, and other complex generic categories.
  • Natco Pharma: Indian specialty generics company with oncology, immunosuppressant, and complex API focus. Comparable to Concord in niche complex generics and in competing for USFDA ANDA approvals in regulated therapeutic segments.

Broad incumbents

  • Sun Pharmaceutical Industries: India's largest pharmaceutical company with a broad generics, specialty, and API portfolio including sterile injectables and fermentation-derived products. Operates as a much larger incumbent that overlaps with Concord in immunosuppressants and global generics.
  • Lupin Limited: Large Indian generics and API manufacturer with USFDA-approved manufacturing. Overlaps with Concord in APIs and complex formulations across regulated and emerging markets; broader portfolio but similar regulated-market strategy.
  • Recipharm: Global CDMO with sterile fill-finish and API capabilities. Comparable to Concord on the CRAM/formulation side for global pharma companies seeking outsourced sterile manufacturing.

Emerging players

  • Piramal Pharma Solutions: CDMO arm of Piramal Pharma with strong contract development and manufacturing capabilities for APIs and sterile injectables. Direct competitor to Concord's CRAM business, particularly for fermentation and complex injectable CDMO engagements.

Regional players

  • Strides Pharma Science: India-based specialty generics company focused on softgel, oral solids, and other regulated-market formulations. Comparable to Concord's formulation business in regulatory complexity and emerging/regulated market reach.

Others

  • Sequent Scientific: Indian fermentation-based API and animal health manufacturer with significant fermentation capabilities. Adjacent peer sharing the fermentation platform technology paradigm relevant to Concord's API manufacturing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Concord Biotech social profiles

Digital presence

Concord Biotech compliance and trust

Trust signal

Compliance11 records

Concord Biotech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Concord Biotech leadership team

Management profile

Number of profiles

Profiles10 records

Concord Biotech subsidiaries and ownership

Company hierarchy

Subsidiaries6 records

Concord Biotech funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Concord Biotech M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Concord Biotech

What does Concord Biotech do?

Concord Biotech Limited develops, manufactures, and commercializes fermentation-based Active Pharmaceutical Ingredients (APIs) and finished formulations across immunosuppressants, oncology, anti-bacterials, and anti-fungals. The company operates four manufacturing facilities in Gujarat, India with 1,250 m³ combined fermentation capacity and 802 million units/year oral solid dosage capacity, supplying global pharmaceutical companies through direct B2B sales and USFDA-approved ANDAs. It also provides Contract Research and Manufacturing Services (CRAM) to pharmaceutical partners globally.

Is Concord Biotech a public or private company?

Concord Biotech is a public company. It is classified as public and is currently operating.

When was Concord Biotech founded?

Concord Biotech was founded in 2000. It employs 1,001 to 5,000 people.

Where is Concord Biotech based?

Concord Biotech is headquartered in Ahmedabad, India, in the Asia region.

How does Concord Biotech make money?

Three revenue lines are on record. API Manufacturing & Sales are the primary driver. The others are finished Formulations and contract Research & Manufacturing (CRAM).

Who are Concord Biotech's main competitors?

Direct peers on record are Biocon Limited, Aurobindo Pharma, Dr. Reddy's Laboratories and Natco Pharma. Broad incumbents are Sun Pharmaceutical Industries, Lupin Limited and Recipharm. Piramal Pharma Solutions is listed as an emerging player. Strides Pharma Science is listed as a regional player. Sequent Scientific is listed as an others.

Does Concord Biotech have an API?

No public API is recorded for Concord Biotech.

What industry is Concord Biotech in?

Concord Biotech's product category is Biopharmaceutical Manufacturing. Its primary akta.pro industry code is HLAGABAA, Small-Molecule API & Intermediates CDMO, with a secondary code of HLAIABAG, Generic APIs & Intermediates (Active Ingredients). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BusinessLineConcord Biotech: Recovering business momentum and new ventures support growthConcord Biotech reported 26% year-on-year revenue growth in H1FY27, with an EBITDA margin of 33%. The company's base API business expects 18-19% annual growth, while injectables and CDMO divisions add potential revenue. Management sees margin pressure easing as new ventures scale.The Times of IndiaBonus issue alert! Last day to buy this Rakesh Jhunjhunwala-backed smallcap pharma stock for 1:1 bonus bonanzaConcord Biotech announced a 1:1 bonus issue, with November 4 as the record date and November 5 as the allotment date. Rakesh Jhunjhunwala's firm held about 24% stake as of September quarter. The stock has fallen over 15% in one month.CNBCTV18Concord Biotech posts double-digit profit growth in Q2, but margins take a hit - CNBC TV18Concord Biotech reported an 11.12% year-on-year rise in Q2 net profit to ₹70.65 crore, with revenue up 25.1% to ₹309.07 crore. EBITDA margin narrowed by 207 basis points to 33.91% as total expenses rose 26.03% to ₹223.10 crore. Shares closed at ₹1,388.90, up 5.93%.CNBCTV18Concord Biotech announces 1:1 bonus share issue; shareholders to get one free share for each held - CNBC TV18Concord Biotech's board approved a 1:1 bonus share issue, giving shareholders one free share for each held, with 10.46 crore shares to be issued. The company's paid-up capital will double to ₹20.92 crore, and the bonus is expected to be completed by November 22, 2026.Zee BusinessFirst-Ever Bonus Issue: Pharma company to consider free shares for shareholdersConcord Biotech's board will meet on September 23 to consider a bonus equity share issue for existing shareholders, the company's first such proposal. Shares rose nearly 5% in early trade on September 21, and the company has not disclosed the bonus ratio or record date.CNBCTV18Bonus Alert: Stock with significant Jhunjhunwala family stake set to reward shareholders - CNBC TV18Concord Biotech's board will meet on September 23 to consider a bonus issue proposal, subject to shareholder approval. The Jhunjhunwala family holds 24.09% of public shares, and this would be the company's first bonus issue. The stock has risen 12.3% year-to-date.Business StandardConcord Biotech's Valthera unit completes US FDA audit with one procedural observationConcord Biotech said the US FDA completed its inspection of its Valthera Formulation Facility in Gujarat with one minor procedural observation. The company will submit a response within the stipulated timeline and expects no material impact on operations or supplies.ScanXConcord Biotech to host analyst meet on Sep 23 in AhmedabadConcord Biotech will host a group analyst meeting on September 23, 2026, in Ahmedabad as part of the JP Morgan Healthcare Trip. The session is scheduled for 12:30 pm, and discussions will be limited to publicly available information, with no unpublished price-sensitive information shared.Business StandardVolumes spurt at Concord Biotech Ltd counterConcord Biotech Ltd saw a 127.52-fold volume spurt on BSE, trading 21.09 lakh shares by 10:46 IST. Other stocks like Granules India, Sapphire Foods, New India Assurance, and Craftsman Automation also recorded volume surges, with prices moving in various directions.ScanXConcord Biotech to host investor meet on August 26 in AhmedabadConcord Biotech will host an investor meet organized by Phillip Capital PCG in Ahmedabad on August 26, 2026, where company officials will address analysts and institutional investors using only publicly available information. The meeting follows the company's strong Q1 FY27 performance, which saw revenue rise 26% to ₹257 crore driven by a 42% surge in API sales and 46% growth in exports.